The emergence of drug resistance in avian influenza virus (AIV) is a serious concern for public 31 health. Neuraminidase (NA) isolated from a fatal case of avian-origin H10N8 influenza virus 32 infection was found to carry a drug-resistant mutation, NA-Arg292Lys (291 in N8 numbering). In 33 order to understand the full potential of H10N8 drug resistance, the virus was first passaged in the 34 presence of the most commonly used neuraminidase inhibitors (NAIs), oseltamivir and zanamivir.
Introduction 8 122 to be at 2%; after 1 passage, it increased quickly to 34%, and became absolute dominant (90%) 123 ( Fig 1B and 2) . 124 In addition to these two NA substitutions, several substitutions occurred on the HA and other 125 certain internal genes. Two HA substitutions, Lys167Glu and Ile413Thr, were pre-existing at the 126 frequency of 49% and 48% respectively, and both became dominant under oseltamivir/ zanamivir 127 treatment and kept steady along cell passages with the increase of drug concentration. Importantly,
128
Val139Ile in Polymerase basic protein 2 (PB2) arose and became dominant in the first passage of 129 zanamivir treatment, with the frequency of 81%. However, this was not observed in oseltamivir 130 treatment passages. One common substitution Cys95Phe in Polymerase acidic protein (PA) 131 occurred in both treatment passages. PA Cys95Phe also pre-existed in the drug-free treatment with 132 frequency of 12%, which showed a slow increasing trend and became dominant at passage 7 in 133 oseltamivir treatment. Meanwhile, in zanamivir treatment passages, it became absolute dominant 134 within 3 passages and levelled off. Another PA substitution Val91Leu was only observed in 135 oseltamivir treatment. This mutation pre-existed in the drug-free treatment control at a frequency 136 of 10% and showed a fluctuating trend along passages. Other two substitutions, HA Gly89Arg and 137 M1 Gln158Arg also showed fluctuating trends along oseltamivir treatment passages. Fluctuating 138 trends for HA Gly89Arg mutation was also observed in zanamivir treatment passages (S1 Fig and   139 Fig 2) . 140 Collectively, we can find that most of these substitutions are pre-existing in the original NAI-free 141 cultures. These pre-existing substitutions might be the natural selection pools when under drug 142 treatment. Correlation analysis of these substitutions using their frequencies values found several 143 strong links: one negative link between HA 179Arg and M1 Gln158Arg, one negative link between 144 HA 179Arg and PA Cye95Phe along oseltamivir treatment; one positive link between NA 9 145 V116Asp and 292Arg. These results suggest that synergy might exist along the dynamic changes 146 of these substitutions, which will be further studied in the future.
147
Reduced Substrate Affinity and Inhibition of N8-Arg292Lys and N8-Val116Asp
148
NA was prepared according to the previously reported methods [29] [30] [31] laninamivir is similar to that of zanamivir, with 10-fold and 90-fold lower potencies, respectively.
158
On the other hand, Arg292Lys showed much higher resistance to peramivir with a 3,169-fold 159 increase in mean IC 50 value, while Val116Asp exhibited a moderate 20-fold reduced sensitivity 160 (Table 1) . Interestingly, the oseltamivir-zanamivir hybrid inhibitor, MS-257 was found to be the The crystal structures of native N8, Val116Asp and Arg292Lys were determined at resolutions of 166 1.9 Å, 1.9 Å and 1.6 Å, respectively (S2 Table) . The apo structures of N8 wildtype, Val116Asp 10 167 and Arg292Lys showed similar overall active site arrangements, with some differences observed 168 regarding Gln136, Thr148, Glu276 and Tyr406 (Fig 3) . Specifically, the conformations of 150- and Glu276 between these two native structures exhibit different conformations. All these 173 observed conformational differences explain why the two N8 mutants have lower affinity to the 174 substrate compared to N8 wildtype.
175

A Distinct Mechanism of Arg292Lys Drug Resistance in Group 1 N8
176
To understand the mechanisms of N8 drug resistance, inhibitor complex structures with wildtype 177 or mutant N8 were compared. The crystal structures of wildtype N8 complexed with zanamivir, 178 oseltamivir, laninamivir and peramivir were determined at resolutions of 1.8 Å, 2.1 Å, 1.8 Å and 179 2.0 Å, respectively (S3 Table) . N8-Arg292Lys complexes were determined at resolutions of 1.9 180 Å, 1.8 Å, 2.0 Å and 1.8 Å for zanamivir, oseltamivir, laninamivir and peramivir, respectively (S4 181   Table) . Binding of oseltamivir, zanamivir, peramivir and laninamivir to wildtype H10N8 NA 182 resembles that of typical group 1 NA binding ( Arg292 is part of the NA tri-arginine cluster that forms strong ionic interactions with the first-190 generation NAI carboxylates. In the structures of N8-Arg292Lys complexed with the four NAIs,
191
Lys292 interacts with the carboxylate group of NAIs by a bridging water molecule (Fig 4A, C, E 192 and G). The Glu276 adopts similar conformation in N8-Arg292Lys-zanamivir and laninamivir 193 complexes ( Fig 4C and G) , but slightly differ in oseltamivir and peramivir-complexes ( Fig 4A and 194 E).
195
The binding of oseltamivir to N8 (group 1 NA) and N9 (group 2 NA) was carefully compared (Fig 196 4B, D, F and H). The flexibility of residue Glu276 is observed in the N9-Arg292Lys oseltamivir 197 complex structure, but only a slightly shift in the N8-Arg292Lys oseltamivir complex structure.
198
Specifically, in N8-Arg292Lys, Glu276 rotates towards Arg224 for optimal oseltamivir binding, 199 which results in a mild shift of the oseltamivir hydrophobic group (1.11 Å). In contrast, the side 12 211
The guanidine group of zanamivir compensates the Val116Asp resistant N8 substitution 212 In order to understand the mechanism of Val116Asp resulting in more severe resistance to 213 oseltamivir than zanamivir, the zanamivir and oseltamivir complex structures of N8-Val116Asp 214 were determined at resolutions of 1.9 Å and 2.1 Å, respectively (S5 Table) . The 150-loop of 215 inhibitor bound-N8 (Val116Asp) complexes exhibited closed conformation, in which the Asp151 216 interacts with inhibitors. When compared the oseltamivir complex-N8 wild type with that of the 217 Val116Asp mutant, it was found that the side chain of Asp151 in N8 wildtype hydrogen bonds to 218 C4-amino group of oseltamivir with a distance of 2.70 Å, while the corresponding distance in N8-
219
Val116Asp was found to be 3.34 Å. In the case of zanamivir complexed structures, oxygen atom NAs.
237
The Val116Lys mutation was the most intriguing N8 substitution. It is challenging to predict a 238 precise mechanism for NAI resistance, because the site of mutation is distal from the active site 239 frame work. Prior to solving the crystal structures, we anticipated that the Val116Asp substitution 240 might affect the interaction between Arg118 and the carboxylate group of the inhibitor, however 241 contrary to expectation, the N8-Val116Lys complex structures clearly suggested that this is not 242 the case and the loss of Tyr347-inhibitor interaction as the resistance mechanism. Tyr347 is found 
248
Val116Lys also resulted in an altered conformation of the 150-loop residue Thr148 (Fig 3) . It is 249 possible that the further changes observed in the loop residues 146-148 upon oseltamivir binding 250 might affect the ionic interaction of Asp151 with the oseltamivir amino group (Fig 5) Zanamivir and laninamivir are more similar to the human sialic acid, N-acetylneuraminic acid, 255 than oseltamivir and peramivir, and therefore should be less susceptible to drug-resistance. Of the 256 4 clinical NAIs, zanamivir bound to both mutants in the most optimal conformation, whereas 257 oseltamivir binding was the least optimal. Resistance of both N8 variants to zanamivir and 258 laninamivir was also lower than that of oseltamivir and peramivir.
259
Some questions remain from the present analysis, including why peramivir was the most potent 260 inhibitor of wildtype N8 despite lacking any Tyr347 interactions. Moreover, binding of the prodrug 261 laninamivir octanoate (CS-8958) to N8 was distinct from group 1 09N1 and similar to group 2 N2, 262 which indicates that NAI binding is not always group specific.
263
In summary, our current study revealed the 4-clinical available NAI resistant substitutions for N8 264 and the underlying mechanisms have also been structurally delineated, which will help for next- was then allowed to grow in the presence of a series of 2-fold oseltamivir and zanamivir dilutions.
292
The virus concentrations used in the selection protocol varied, depending on the HA titer in the 293 preceding passage and about 1 ml aliquot of viral stock culture supernatant from the preceding 294 passage was used to infect the fresh cell monolayer cells. The HA titer was determined after each 295 passage to estimate the amount of virus needed for infection. This selection was carried out for a 296 total of 8 passages for both inhibitors in triplicates. Drug concentration ranged from 80 μM to 297 10.24 mM for oseltamivir and 20 μM to 2.56 mM for zanamivir. All conditions were carried out 298 in triplicates. 
